Skip to main content

Quest Diagnostics guidance

  • DGX · NYSE
  • Healthcare
  • Health Care Services
  • S&P 500
$262.21+1.01%Close 16 Nov 2026 · Market value $28.35B

In its results release of 22 Oct 2026 (Q3 FY2026), Quest Diagnostics gave 5 forecasts in figures, among them revenue of $12.06B to $12.11B for FY2026. Over the last two years, results landed above the company's own last range 4 of 4 times, within it 0 and below it 0.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 22 Oct 2026

MeasurePeriodGuidanceAs stated
RevenueFY2026$12.06B to $12.11BFull year 2026 revenues now expected to be between $12.065 billion and $12.105 billion
Revenue growthFY2026+9.3% to +9.7%Net revenues increase 9.3% - 9.7%
EPS growth · AdjustedFY2026+15.4%Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025
EPSFY2026$10.21 to $10.31Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35
Capital expendituresFY2026$550MCapital expenditures $550 million

Source: the company's earnings release.

Guidance against results above 4 · within 0 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$12.06B to $12.11BRaised 3 times—To come
Revenue growthFY2026+9.3% to +9.7%Raised 3 times—To come
EPSFY2026$10.21 to $10.31Raised 3 times—To come
EPS · AdjustedFY2026$10.50 to $10.70Given once—To come
EPS growth · AdjustedFY2026+15.4%Raised once, lowered once—To come
Capital expendituresFY2026$550MUnchanged—To come
RevenueFY2025$10.96B to $11.00BRaised twice$11.04BAbove the range
Revenue growthFY2025+11% to +11.4%Raised twice+11.78%Above the range
Capital expendituresFY2025$500MUnchanged$527MAbove the range
RevenueFY2024$9.80B to $9.85BGiven once$9.87BAbove the range
Revenue growthFY2024+5.9% to +6.5%Given once+6.7%Above the range
Capital expendituresFY2024$420MGiven once$425MAbove the range

DGX in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.